Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.
Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal.
India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.
The US District Court for the District of New Jersey has found in favour of Teva Pharmaceutical Industries Ltd in its patent infringement case with Mylan over Parkinson’s disease drug Azilect.
Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.
Austria has become the first country in the EU to ratify consent to the Unified Patent Court.
Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.
US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.